We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Meta-Analysis Finds Home-Based Test Effective for Colorectal Cancer Screening

By LabMedica International staff writers
Posted on 10 Feb 2014
The largest and most comprehensive evidence review to date indicates that the patient-friendly and simple home-based test is a valuable colorectal cancer-screening tool.

Tests that require patients to collect a single stool sample at home and then send it to a lab for analysis detect about 79% of colorectal cancers (CRCs), according to a new evidence review now published by Lee, et al. More...
in the journal Annals of Internal Medicine, February 4, 2014. The review of 19 studies examining eight different fecal immunochemical tests (FITs) also finds that such tests will correctly identify about 94% of patients who do not have cancers of the rectum or colon. "Now we also know that [FIT] is a great tool for assessing which patients have [this] cancer and which patients don’t,” said Beth Liles, MD, clinical investigator at the Kaiser Permanente Center for Health Research in Portland (OR, USA) of Kaiser Permanente (Oakland, CA, USA).

“The American Cancer Society and other professional organizations have recommended FIT as a screening tool for CRC since 2008, but there are still many people who don’t know about it,” said Jeffrey Lee, MD, MAS, and postdoctoral researcher at the Kaiser Permanente Division of Research and at the University of California, San Francisco. Unlike older stool tests, FIT does not require people to restrict their diets or to stop taking medications. Conducted annually, FIT detects small amounts of blood in the stool; people who test positive are much more likely to have CRC and so would need a follow-up colonoscopy.

The evidence review found that the FITs were fairly sensitive. On average, the tests detected 79% of CRCs with only one round of testing. The tests were also highly specific: on average, 94% of people who did not have cancer tested negative with a single FIT. By comparison, studies indicate that the at-home fecal occult blood test (FOBT) test, which requires 3 stool samples as well as medication and dietary restrictions, detects only about 13% to 50% of CRCs after a single round of testing.

According to the review, no single FIT performed markedly better than another, but the authors caution that there was only one study comparing brands head-to-head. Most of the FITs required collection of only one stool sample. Surprisingly, brands requiring two or three stool samples were no more accurate than those requiring only one.

The 19 studies included 80 to 27,860 patients, with the average age ranging from 45 to 63. Study settings varied. Eligibility criteria were to include all studies evaluating the diagnostic accuracy of FITs for CRC in asymptomatic, average-risk adults. The review was limited to studies in the English language. Two reviewers independently extracted data and critiqued study quality. In 12 of the studies, all patients took the FIT and received a colonoscopy. In seven studies, patients only had a colonoscopy to follow-up on a positive FIT. Approximately 2 years later, researchers followed up with patients who had had a negative FIT to determine whether they had been diagnosed with CRC.

FITs were concluded to be moderately sensitive, highly specific, and with high overall diagnostic accuracy for detecting CRC. Sensitivity for CRC improved with lower assay cutoff values for a positive test result but with a corresponding decrease in specificity. The study was part of Kaiser Permanente’s ongoing efforts to promote prevention and evidence-based care. Another Kaiser Permanente study also found that patients who visited their doctor for any reason were nearly 6 times more likely to be screened for CRC compared to those who did not visit their doctor.

Related Links:

Kaiser Permanente
Kaiser Permanente Division of Research



New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Pathology

view channel
Image: The new system allows surgeons to identify genotyping of brain tumors and determine optimal resection margins during surgery (Photo courtesy of Nagoya University)

New Technique Detects Genetic Mutations in Brain Tumors During Surgery within 25 Minutes

Determining the genetic profile of brain tumors during surgery is crucial for improving patient outcomes, but conventional analysis methods can take up to two days, delaying critical decisions.... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.